Mahavir Advanced Remedies (Delisted) financials and balance sheet

BSE: 531689Pharmaceuticals & Biotechnology

Last traded ₹150.65 on 6 Jan 2015

Delisted on 23 Nov 2023.

7 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Mahavir Advanced Remedies annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹0.24 Cr, year to Mar 2011Back to profit in the year to Mar 2014, ₹0.14 Cr

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2014

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue0.1
  2. Other income+0.2
  3. Profit before tax0.1
  4. Net profit0.1

Profit and loss

Standalone, ₹ crore, years to March.Mahavir Advanced Remedies quarterly results

₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014
Revenue from operations0.070.020.190.240.210.150.10
–––––––
Materials and goods bought0.020.00–0.16–––
Depreciation and amortisation0.060.060.040.040.04––
Other income––––––0.22
Profit before one-off items and tax–−0.10−0.06−0.05−0.02−0.040.14
One-off items–––––−0.11–
Profit before tax−0.09−0.10−0.06−0.05−0.02−0.150.14
Net profit−0.09−0.10−0.06−0.05−0.02−0.150.14
Net margin−125.0%−577.8%−32.8%−19.6%−8.7%−105.5%134.0%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2008, Mar 2009, Mar 2010, Mar 2011 and Mar 2012: the statement does not state its finance costs, which operating profit is worked out from, so operating profit is not given. Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2013 and Mar 2014: the statement does not state its finance costs or depreciation, which operating profit is worked out from, so operating profit is not given.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2013Mar 2014
Earnings per share−₹0.13₹0.12
Diluted earnings per share−₹0.13₹0.12
Market cap at the year end (₹ crore)–222

Ratios

Standalone, years to March.

RatioMar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014
Revenue growth−73.5%966.7%25.0%−14.2%−29.6%−29.0%

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2014.

Measure5 years3 years
Revenue growth, yearly rate41.7%−24.6%
Net margin, average−6.5%6.6%